Drug
Hmpl 523
Hmpl 523: highest development phase Phase 2/3, developed by Hutchmed, United Therapeutics. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Hutchmed, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| HMPL-523(300mg PO QD) NCT05535933 | Phase 2/3 | Warm Antibody Autoimmune Hemolytic Anemia |
| HMPL-523 NCT06291415 | Phase 1 | Immune Thrombocytopenia |
| HMPL-523 NCT05318820 | Phase 1 | Healthy Subject |
| HMPL-523 Acetate Tablets (Test Formulation) NCT07331194 | Phase 1 | Healthy |
| HMPL-523 NCT03779113 | Phase 1 | Non Hodgkin Lymphoma |
Latest
Follow Hmpl 523 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.